Cleveland Clinic researchers have announced the next step they will take with their novel study of a vaccine intended to prevent triple negative breast cancerthe most aggressive and lethal form of the disease.
Said study, financed by the Department of Defense of the United States, already in phase 1b will enroll cancer-free people with a high risk of developing breast cancer, who have decided to voluntarily undergo a prophylactic mastectomy to reduce your risk.
People in that category often carry gene mutations that put them at risk of developing triple-negative breast cancer or have a high familial risk of developing any type of breast cancer.
You can read: Doctor assesses the health of a woman in the climacteric stage
The study, which will be conducted at Cleveland Clinic’s main campus, will assess safety and monitor immune response. It will include approximately 6 to 12 patients and is expected to be complete by the end of 2023.
Study participants will receive three vaccines administered two weeks apart and will be closely monitored for side effects and immune response.
The phase 1b clinical trial, conducted in association with Anixa Biosciences, Inc.follows the ongoing Phase 1a study, which opened in 2021 and is expected to be completed in the fourth quarter of 2023.
